Key result
Gemcitabine therapy triggered atrial fibrillation in a 65-year-old man being treated for non-small cell lung cancer.
Why the study?
Does gemcitabine therapy induce atrial fibrillation in patients with non-small cell lung cancer?
Case Report (n=1)
Does gemcitabine therapy induce atrial fibrillation in patients with non-small cell lung cancer?
Gemcitabine treatment may rarely induce atrial fibrillation, highlighting the need for close monitoring of at-risk patients during chemotherapy.
Gemcitabine may rarely trigger AF in NSCLC; leaves open causality and any monitoring implications.
BACKGROUND: Gemcitabine, a pyrimidine analogue, is a cell cycle-specific antineoplastic agent that is structurally related to cytarabine. Major side effects of the treatment with gemcitabine are hepatic dysfunction, myelosuppression, renal impairment and pulmonary toxicity. Development of atrial fibrillation (AF) during gemcitabine treatment is very rare and was reported in only 2 case reports in the literature. CASE REPORT: We report the case of a 65-year-old man who developed AF under gemcitabine therapy for non-small cell lung cancer (stage IIIB). In this patient, AF was intrinsically associated with chemotherapy administration which triggered arrhythmia. CONCLUSION: Although AF caused by gemcitabine appears to be rare, patients at risk of developing atrial fibrillation should be closely monitored for this complication.
No takes yet. Share an insight, caveat, or question.
Tavıl et al. (2007) conducted a case report in non-small cell lung cancer (stage IIIB) (n=1). Gemcitabine was evaluated on Atrial fibrillation. Gemcitabine therapy triggered atrial fibrillation in a 65-year-old man being treated for non-small cell lung cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: